A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2018
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors Forest Laboratories
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 19 May 2013 Results will be presented at the American Psychiatric Association (APA) annual meeting, according to a Forest Laboratories media release.
- 10 Apr 2012 Actual patient number is 203 according to ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History